Jens Schneider-Mergener, a serial entrepreneur, has become chief executive officer of Adrenomed AG, a privately financed company with a lead product for septic shock. He succeeds Gerald Möller, who joins Adrenomed’s Supervisory Board.
Dr Schneider-Mergener is the co-founder of 3B Pharmaceuticals GmbH, a German radiopharmaceutical company and Phavaris BV, a Dutch biotech working on a treatment for hereditary angioedema. He also founded Jerini AG which was acquired by Shire Plc in 2008.
Dr Schneider-Mergener studied chemistry and biochemistry at the University of Bielefeld and at Ludwig-Maximilians-University in Munich where he received a doctorate degree. He worked as a post-doctoral scientist at the California Institute of Technology, US where he is credited with the discovery of the HIV-1 protease.
This discovery was reported in: Wlodawer, A., Miller, M., Jaskolski, M., Sathyarayana, B. K., Baldwin, E., Weber, I. T., Selk, L., Clawson, L., Schneider, J. and Kent, S. B. H. (1989). Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621; and Schneider, J. and Kent, S. B. H. (1988). Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 Protease. Cell 54, 363-368.
Adrenomed announced the appointment on 29 August 2019.
Copyright 2019 Evernow Publishing Ltd.